Mainz Biomed NV's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered undervalued, ranking 64 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.00.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Mainz Biomed NV is 5.66, ranking 69 out of 75 in the Healthcare Providers & Services industry. Its financial status is stable, and its operating efficiency is low.
Key Metrics
The current valuation score of Mainz Biomed NV is 8.02, ranking 18 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -0.04, which is 0.00% below the recent high of -0.04 and -5832.15% above the recent low of -2.51.
The current earnings forecast score of Mainz Biomed NV is 8.00, ranking 28 out of 75 in the Healthcare Providers & Services industry. The average price target is 14.00, with a high of 14.00 and a low of 14.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Mainz Biomed NV is 2.15, ranking 73 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 1.39 and the support level at 0.71, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Mainz Biomed NV is 1.78, ranking 67 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
